The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > ARCHIVE
ARCHIVE
- Life Science Units of Tomen, Nichimen to Merge into New Company
January 22, 2001
- CPAC Members Fail to Form Consensus on Production, Supply of Blood Preparations
January 22, 2001
- MEDICAL DEVICE NEWS IN BRIEF
January 22, 2001
- GlaxoSmithKline Opens Call-Centre for Health Professionals, Patients
January 22, 2001
- 16 Ingredients to Be Added to Orange Book
January 22, 2001
- PDA International Congress to Be Held from Feb. 19 to 21
January 22, 2001
- Company Leaders Stress Importance of Globalization, IT Revolution
January 22, 2001
- REGULATORY NEWS IN BRIEF -1-
January 22, 2001
- Fujisawa to Reorganize European Operations
January 22, 2001
- Drug Industry Should Earn More Foreign Currency: Mr Fujiyama of FPMAJ
January 22, 2001
- REGULATORY NEWS IN BRIEF -2-
January 22, 2001
- FJPWA Opposes Harsher Changes in NHI Price Revision Rule: Mr Kojima
January 22, 2001
- ON THE MOVE
January 22, 2001
- JPMA Committee Calls For Deregulation to Allow Supply of Information Via Internet
January 22, 2001
- JMA to Clarify Details of Its Grand Healthcare Design
January 22, 2001
- MRs Should Take Cooperation between Medical Facilities into Account: Seminar
January 22, 2001
- Handicapped Persons to Be Given Opportunity to Become Doctors, Dentists, Nurses
January 22, 2001
- BUSINESS NEWS IN BRIEF -1-
January 22, 2001
- 2001 Meeting Schedule of the Japanese Association of Medical Sciences
January 22, 2001
- BUSINESS NEWS IN BRIEF -2-
January 22, 2001
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…